Skip to main content

Table 1 Clinical characteristics of subjects in this study

From: Urinary biomarker discovery in gliomas using mass spectrometry-based clinical proteomics

GroupNSex (M/F)AgeHistology#
Discovery phase 
Gliomas52/345.20 ± 10.50WHO-II (1); WHO-IV (4)
Validation phase 
Gliomas106/444.78 ± 12.20WHO-II (2); WHO-III (2); WHO-IV(6)
Meningioma52/354.60 ± 9.42--
Moyamoya63/337.67 ± 9.69--
Healthy control125/742.17 ± 8.42--
  1. Glioma grade classified as World Health Organization (WHO) grades I–IV
  2. M male; F female